Se-Young Park

Se-Young Park

Auto-generated profile, based on publicly available information

Se-Young Park

Department of Oral Biology, BK21 Four Project, Yonsei University College of Dentistry, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2023 in BMB Reports
Verified
Journal Article
Open access
PDF file
SPSe-Young Park
Se-Young Park
BHByeong-Oh Hwang
Byeong-Oh Hwang
NSNa-Young Song
Na-Young Song
Se-Young Park, Byeong-Oh Hwang & Na-Young Song. BMB Reports 2023;56:365-73. https://doi.org/10.5483/BMBRep.2023-0064

28 November 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
SPSe-Young Park
Se-Young Park
KSKyuwon Son
Kyuwon Son
JKJiwoo Kim
Jiwoo Kim
KKKyeongah Kim
Kyeongah Kim
SJSungmin Joo
Sungmin Joo
NSNa-Young Song
Na-Young Song
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy; however, their use is frequently associated with immune-related adverse events (irAEs). In this study, anti-PD-L1 therapy exacerbates muscle wasting in tumor-bearing male mice despite its anti-tumor efficacy, accompanied by an accumulation of CD8+ T cells in muscle. Single-cell RNA sequencing identifies these cells as tissue-resident memory-like CD49a+ CD8+ T cells. While CD8+ T cell depletion prevents muscle wasting, it compromises the anti-tumor efficacy of anti-PD-L1. To resolve this paradox, we identify cathepsin L (CTSL) as a dual-target capable of suppressing both tumor progression and CD8+ T cell-mediated muscle wasting, through integrative transcriptomic analysis. Pharmacological inhibition of CTSL not only mitigates anti-PD-L1-induced muscle wasting but also further suppresses tumor growth, potentially via downregulation of BNIP3. Here, we show that CTSL is a dual-action target to uncouple anti-tumor efficacy from muscle-specific irAEs, offering a strategy to improve clinical outcomes of ICIs.